Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.46 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | UGT1A7 | Q9HAW7 | 1/20 | 0.46 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26313777 | 0.90 | TP53 (0.45) | TP53CA12CA9SMN1; SMN2CA2 | |
| SCHEMBL26313787 | 0.84 | TP53 (0.43) | TP53CA12CA9SMN1; SMN2CA2 | |
| SCHEMBL26313790 | 0.84 | CA12 (0.41) | TP53CA12CA9SMN1; SMN2CA2 | |
| Hydrochloric Acid SCHEMBL30321030 | 0.83 | TP53 (0.42) | TP53CA12CA9SMN1; SMN2CA2 | |
| Bromide SCHEMBL30321033 | 0.82 | CA12 (0.42) | TP53CA12CA9SMN1; SMN2CA2 | |
| SCHEMBL26313819 | 0.82 | CA9 (0.45) | CA12CA9SMN1; SMN2CA2RAB9A | |
| SCHEMBL26313789 | 0.80 | MMP2 (0.40) | TP53 | |
| SCHEMBL26313795 | 0.77 | TP53 (0.43) | TP53CA12CA9SMN1; SMN2CA2 | |
| SCHEMBL7158031 | 0.70 | ESR1 (0.44) | — | |
| SCHEMBL14294336 | 0.70 | LMNA (0.52) | SMN1; SMN2RAB9ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257357-A1 | PROBENECID COMPOUNDS FOR THE TREATMENT OF INFLAMMASOME-MEDIATED LUNG DISEASE | NLRP3, PYCARD, NLRP1 | TP53 315/4885CA12 3513/4885CA9 2197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.